News | January 24, 2025
Alivus Life Sciences delivers 12% revenue growth
EBITDA margins expand to 31.3%
EBITDA margins expand to 31.3%
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Subscribe To Our Newsletter & Stay Updated
